Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...

The company emphasized its strategic focus on biosimilars, noting significant investments and a robust pipeline targeting a $200 billion market. While Alvotech highlighted successful product ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...